文献速递妇科

奥戈伏单抗间接免疫联合卡铂-紫杉醇一线治疗晚期卵巢癌的随机II期研究

Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
PubMed 文献 · Gynecol Oncol · 2020-01-06

这项随机II期研究纳入97例III/IV期 optimally cytoreduced 卵巢癌患者,比较标准化疗(CP)与化疗联合奥戈伏单抗免疫(CPO)。中位随访42个月,CPO组中位PFS为41.8个月,CP组为12.2个月(p=0.0027,HR 0.46);CPO组中位OS未达到,CP组为43.2个月(p=0.043,HR 0.35)。

要点

  • CPO组中位PFS 41.8个月 vs CP组12.2个月,HR 0.46。
  • CPO组中位OS未达到 vs CP组43.2个月,HR 0.35。
  • 奥戈伏单抗未增加化疗毒性谱。

核心结论

  • 在 optimally resected III/IV 期卵巢癌一线治疗中,卡铂-紫杉醇联合奥戈伏单抗间接免疫较单纯化疗显著改善PFS和OS。

研究设计与样本

  • 随机II期研究,纳入97例III/IV期 optimally cytoreduced 卵巢癌患者,来自美国和意大利的学术中心及私人诊所,随机分为CP组(50例)和CPO组(47例)。
  • 主要终点为细胞免疫反应的转化评估,PFS和OS为次要终点。

主要发现

  • 中位随访42个月,CPO组中位PFS为41.8个月(95%CI 21.8-N.E.),CP组为12.2个月(95%CI 10.4-18.6),p=0.0027,HR 0.46(95%CI 0.28-0.7)。
  • CPO组中位OS未达到(95%CI 45.2-N.E.),CP组为43.2个月(95%CI 31.8-N.E.),p=0.043,HR 0.35(95%CI 0.16-0.74)。
  • 奥戈伏单抗治疗未改变CP的毒性谱。
  • 由于技术问题,主要终点CA125 ELISPOT检测性能不一致,结果不可评估。

临床怎么用

  • 对于 optimally resected III/IV 期卵巢癌,可考虑在卡铂-紫杉醇一线化疗基础上联合奥戈伏单抗间接免疫以改善PFS和OS。

局限性

  • 主要终点CA125 ELISPOT因技术问题不可评估。
  • 样本量较小(97例),为II期研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This randomized phase II study tested the hypothesis that schedule dependent chemo-immunotherapy with oregovomab improves progression free survival (PFS) and overall survival (OS) in optimally resected, Stage III/IV ovarian cancer. METHODS: Patients from both academic centers and private practice in the US and Italy with Stage III/IV optimally cytoreduced ovarian cancer were randomized to standard six cycle IV carboplatin-paclitaxel chemotherapy (CP) versus CP plus four immunizations with oregovomab (CPO). A translational assessment of a cellular immune response was the primary endpoint; PFS and OS were measured as secondary endpoints. FINDINGS: 97 patients at thirteen centers were accrued to the protocol, 47 to CPO and 50 to CP. Technical issues led to inconsistent performance of the primary CA125 ELISPOT leading to unevaluable results. At a median follow up of 42 months, PFS and OS outcomes revealed an unexpectedly large treatment effect for CPO relative to CP alone, with median PFS of 41.8 months (95% C.I.: 21.8 - N.E.) for CPO and 12.2 months (10.4-18.6) for CP (p = 0.0027, HR 0.46, CI 0.28-0.7). For OS, the median for CPO has not yet been reached (NE) (45.2-NE) and for CP was 43.2 months (31.8-NE) (p = 0.043, HR 0.35, CI 0.16-0.74). The oregovomab treatment resulted in no change in toxicity profile from CP. INTERPRETATION: The previously identified potential clinical benefit of IV CP when administered with oregovomab was further refined in this randomized phase II study. Increases of PFS and OS of statistically and clinically significant magnitude were evident in this study of a front line chemo-immunotherapy treatment of ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Brewer M, Angioli R, Scambia G, et al. Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. Gynecol Oncol. 2020. PMID: 31916979. doi:10.1016/j.ygyno.2019.12.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。